Sexual Arousal Disorder

2
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Palatin Technologies
1 program
1
BremelanotidePhase 2Peptide
Pfizer
PfizerNEW YORK, NY
1 program
1
BremelanotidePhase 2Peptide1 trial
Active Trials
NCT00425256CompletedEst. May 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerBremelanotide

Clinical Trials (1)

NCT00425256PfizerBremelanotide

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

Start: Feb 2006Est. completion: May 2007
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space